ReviewEndocrinology and metabolism clinics of North America2011
New hormonal therapies for castration-resistant prostate cancer.
Review in Endocrinology and metabolism clinics of North America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum.The Journal of steroid biochemistry and molecular biology · 2013Trial
- Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation.The Journal of clinical endocrinology and metabolism · 2013Trial
- Diane-35 and metformin therapy in rats with endometrial lesions induced by dihydrotestosterone exposure.Annals of translational medicine · 2023Article
- Allosteric alterations in the androgen receptor and activity in prostate cancer.Endocrine-related cancer · 2017Review
- Insights into Chemoresistance of Prostate Cancer.International journal of biological sciences · 2015Review
- The link between androgen receptor splice variants and castration-resistant prostate cancer.Hormones & cancer · 2014Review
- Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.International journal of biological sciences · 2014Article
- Metformin targets c-MYC oncogene to prevent prostate cancer.Carcinogenesis · 2013Article
- Article
- Abiraterone in prostate cancer: a new angle to an old problem.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Review
- Androgen receptor antagonists in castration-resistant prostate cancer.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Continued activation of the androgen receptor (AR) axis despite castration remains a critical force in the development of castration-resistant prostate cancer (CRPC). Therapeutic strategies designed to more effectively ablate tumoral androgen activity are required to improve clinical efficacy and prevent disease progression. Tumor-based alterations in expression and activity of the AR and in steroidogenic pathways mediating ligand generation facilitate the development of CRPC. This article reviews AR and ligand-dependent mechanisms underlying CRPC progression and the status of novel hormonal therapies targeting the AR axis that are currently in clinical and preclinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.